Grogan serves as Chief Scientific Officer of Ventana and has served as its Director since founding the company in June 1985. Ventana was subsequently purchased by Roche in 2008 for $3.4 billion.[3] Grogan also served as Chairman of Ventana from 1985 to 1995.[2]
Grogan has taught at the University of Arizona College of Medicine since 1979 where he specializes in hematopathology and is now a professor emeritus.[1][2] Among professional associations, he is a Lymphoma Biology Committee member and founding member of the International Lymphoma Study Group (ILSG),[2] which formulated the current classification scheme for clinical practice.[4]
Grogan has authored or co-authored more than 200 papers on lymphoma and myeloma, including contributing to a World Health Organization (WHO) publication, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, that is part of a series on histological and genetic typing of human tumors that covers all leukemia and lymphoma types.[2] It provides an international standard for oncologists and pathologists for use in the design of studies monitoring response to therapy and clinical outcomes.[6] His 2019 autobiography as to Ventana is a 200-page book, Chasing the Invisible: A Doctor's Quest to Abolish the Last Unseen Cancer Cell.
^WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (IARC WHO Classification of Tumours). Lyon: International Agency for Research on Cancer, World Health Organization. 2008. ISBN9789283224310.